The lawsuit, filed in the United States District Court for the Northern District of California under the caption Operating Engineers Construction Industry and Miscellaneous Pension Fund v. PROCEPT BioRobotics Corporation, claims the company artificially inflated its reported U.S. handpiece sales. According to the complaint, PROCEPT utilized a discount program to incentivize bulk orders that far exceeded actual clinical demand for its Aquablation therapy system. These allegedly deceptive practices masked a consistent surplus, exposing the company to undisclosed financial risks.
Investors File Securities Fraud Class Action Against PROCEPT BioRobotics
A securities fraud class action lawsuit now targets PROCEPT BioRobotics Corporation, alleging the medical technology firm misled shareholders regarding product demand. Investors who purchased common stock between February 28, 2024, and February 25, 2026, face a September 22, 2026, deadline to seek lead plaintiff status in the case.
The discrepancy surfaced on February 25, 2026, when PROCEPT revealed that handpiece sales had materially outpaced actual procedures every quarter since early 2023. Following the disclosure, the company’s stock price dropped more than 18%. Kessler Topaz Meltzer & Check, LLP is currently representing investors seeking to address these losses. Those interested in the litigation process have until September 22, 2026, to file for lead plaintiff status, a role that involves directing the litigation on behalf of the broader class.
Comments (0)
No comments yet. Be the first!